JTE 761
Alternative Names: JTE-761Latest Information Update: 28 Nov 2022
At a glance
- Originator Japan Tobacco
- Class Antiallergics
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Hypersensitivity
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Allergy in Unknown (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Autoimmune-disorders in Unknown (PO)
- 31 Oct 2019 Phase-I clinical trials in Autoimmune disorders (PO) before October 2018